DDrare: Database of Drug Development for Rare Diseases

Reldesemtiv (DrugBank: Reldesemtiv)

2 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
3	Spinal muscular atrophy	1

2. Amyotrophic lateral sclerosis [ 508 clinical trials, 530 drugs, (DrugBank: 146 drugs), 170 drug target genes, 221 drug target pathways]

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 508 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03160898 (ClinicalTrials.gov)	July 24, 2017	12/5/2017	A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Reldesemtiv;Drug: Placebo	Cytokinetics	Astellas Pharma Inc	Completed	18 Years	80 Years	All	458	Phase 2	United States;Australia;Canada;Ireland;Netherlands;Spain

3. Spinal muscular atrophy [ 179 clinical trials, 102 drugs, (DrugBank: 26 drugs), 52 drug target genes, 78 drug target pathways]

Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 179 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02644668 (ClinicalTrials.gov)	January 14, 2016	23/12/2015	A Study of CK-2127107 in Patients With Spinal Muscular Atrophy	A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy	Spinal Muscular Atrophy	Drug: Placebo;Drug: Reldesemtiv 150 mg;Drug: Reldesemtiv 450 mg	Cytokinetics	Astellas Pharma Global Development, Inc.	Completed	12 Years	N/A	All	70	Phase 2	United States;Canada